Index RUT
P/E -
EPS (ttm) -2.10
Insider Own 2.72%
Shs Outstand 61.00M
Perf Week 20.67%
Market Cap 1.49B
Forward P/E -
EPS next Y -2.94
Insider Trans -8.26%
Shs Float 59.97M
Perf Month 12.82%
Income -126.09M
PEG -
EPS next Q -0.83
Inst Own 101.57%
Short Float 10.37%
Perf Quarter 28.66%
Sales 168.34M
P/S 8.83
EPS this Y -66.34%
Inst Trans -2.45%
Short Ratio 8.48
Perf Half Y 38.01%
Book/sh 10.96
P/B 2.20
EPS next Y 15.08%
ROA -14.02%
Short Interest 6.22M
Perf Year -11.13%
Cash/sh 9.63
P/C 2.50
EPS next 5Y -
ROE -18.06%
52W Range 16.49 - 28.96
Perf YTD 13.57%
Dividend Est. -
P/FCF 22.30
EPS past 5Y -9.81%
ROI -16.98%
52W High -16.75%
Beta 0.79
Dividend TTM -
Quick Ratio 7.36
Sales past 5Y 70.11%
Gross Margin 93.17%
52W Low 46.21%
ATR (14) 1.25
Dividend Ex-Date -
Current Ratio 7.36
EPS Y/Y TTM -127.34%
Oper. Margin -81.54%
RSI (14) 68.98
Volatility 8.44% 5.22%
Employees 280
Debt/Eq 0.12
Sales Y/Y TTM 2.28%
Profit Margin -74.90%
Recom 1.46
Target Price 35.83
Option/Short Yes / Yes
LT Debt/Eq 0.11
EPS Q/Q -56.17%
Payout -
Rel Volume 0.60
Prev Close 23.63
Sales Surprise -42.44%
EPS Surprise -192.45%
Sales Q/Q 106.80%
Earnings Feb 27 AMC
Avg Volume 733.62K
Price 24.11
SMA20 18.94%
SMA50 9.91%
SMA200 15.48%
Trades
Volume 437,491
Change 2.03%
Date
Action
Analyst
Rating Change
Price Target Change
Apr-16-24 Reiterated
BTIG Research
Buy
$56 → $38
Feb-28-24 Downgrade
Piper Sandler
Overweight → Neutral
$37 → $24
May-19-23 Initiated
BofA Securities
Buy
$42
Dec-06-22 Initiated
Cowen
Outperform
Oct-13-22 Upgrade
Raymond James
Outperform → Strong Buy
$58
Sep-21-22 Initiated
JP Morgan
Overweight
$37
Jul-06-22 Resumed
Canaccord Genuity
Buy
$50
Feb-11-22 Initiated
BMO Capital Markets
Outperform
$54
Jan-21-22 Initiated
SMBC Nikko
Outperform
$60
Dec-15-21 Initiated
H.C. Wainwright
Buy
$61
Oct-15-21 Resumed
BTIG Research
Buy
$56
Feb-24-21 Upgrade
Raymond James
Mkt Perform → Outperform
$58
Mar-04-20 Initiated
Barclays
Underweight
$28
Feb-25-20 Upgrade
Guggenheim
Neutral → Buy
$43
Jan-30-20 Initiated
RBC Capital Mkts
Outperform
$44
Nov-20-19 Resumed
Guggenheim
Neutral
Aug-07-19 Downgrade
Raymond James
Outperform → Mkt Perform
Aug-07-19 Downgrade
Guggenheim
Buy → Neutral
Jun-13-19 Initiated
Mizuho
Buy
Apr-12-19 Initiated
Guggenheim
Buy
Show Previous Ratings
May-03-24 07:01PM
May-02-24 03:31AM
Apr-09-24 08:01AM
Mar-08-24 05:01PM
Mar-07-24 05:00PM
04:01PM
Loading…
Feb-28-24 04:01PM
09:35AM
(Thomson Reuters StreetEvents)
08:38AM
Feb-27-24 05:20PM
04:39PM
04:26PM
(Associated Press Finance)
04:01PM
Feb-20-24 04:31PM
Feb-19-24 03:37AM
Feb-15-24 10:00AM
04:01PM
Loading…
Jan-03-24 04:01PM
09:55AM
Jan-02-24 08:01AM
Dec-30-23 05:02PM
Nov-21-23 04:01PM
Nov-09-23 02:19PM
Nov-08-23 05:21AM
(FierceBiotech.com) -7.01%
Nov-07-23 04:39PM
(Associated Press Finance)
04:01PM
04:01PM
Nov-03-23 12:01PM
Oct-31-23 04:01PM
12:00PM
Oct-26-23 08:01AM
Oct-17-23 04:21AM
09:01AM
Loading…
Sep-27-23 09:01AM
Sep-19-23 04:01PM
Aug-08-23 06:01AM
Aug-07-23 04:02PM
Aug-03-23 05:15PM
04:13PM
(Associated Press Finance)
04:01PM
Jul-27-23 08:01AM
Jul-03-23 08:38PM
Jun-21-23 08:00PM
Jun-18-23 10:00AM
May-30-23 06:01PM
May-09-23 01:49PM
(Thomson Reuters StreetEvents)
May-08-23 05:15PM
04:08PM
04:01PM
May-01-23 04:01PM
Apr-26-23 08:00PM
08:01AM
Apr-17-23 01:31PM
Apr-09-23 01:19PM
Mar-14-23 04:31PM
02:56AM
Feb-28-23 05:10AM
Feb-25-23 07:17AM
Feb-23-23 05:25PM
04:01PM
Feb-20-23 10:00AM
Feb-16-23 04:01PM
Feb-07-23 04:01PM
Jan-26-23 02:33PM
Jan-09-23 08:01AM
Jan-05-23 06:30AM
Jan-04-23 04:01PM
Dec-12-22 03:44PM
10:00AM
Nov-30-22 09:55AM
Nov-25-22 12:00PM
Nov-10-22 04:01PM
09:55AM
09:01AM
Nov-07-22 05:25PM
04:01PM
04:01PM
Nov-03-22 09:01AM
Oct-31-22 04:01PM
Oct-28-22 11:58AM
Oct-14-22 09:41AM
Oct-06-22 08:37PM
Oct-05-22 08:01AM
Sep-09-22 08:01AM
Aug-29-22 06:35AM
Aug-03-22 05:25PM
04:01PM
Aug-02-22 06:30AM
Aug-01-22 11:31AM
Jul-27-22 04:01PM
Jul-01-22 11:59AM
May-26-22 05:01PM
May-13-22 09:18AM
May-07-22 09:30AM
May-06-22 10:24AM
05:38AM
May-05-22 05:25PM
04:01PM
11:26AM
11:12AM
11:07AM
09:31AM
08:45AM
Xencor, Inc. is a biopharmaceutical company, which engages in the development of engineered monoclonal antibody therapeutics to treat severe and life-threatening diseases. Its proprietary technology platform, XmAb, is used to create next-generation antibody product candidates designed to treat autoimmune and allergic diseases, cancer, and other conditions. The company was founded by Bassil I. Dahiyat and Stephen L. Mayo in August 1997 and is headquartered in Monrovia, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Valente Nancy EVP, Chief Development Officer May 02 '24 Sale 23.58 4,745 111,872 55,115 May 03 04:06 PM Dahiyat Bassil I PRESIDENT & CEO Mar 11 '24 Sale 23.50 2,741 64,418 351,894 Mar 12 04:03 PM Desjarlais John R SR. VICE PRESIDENT & CSO Mar 11 '24 Sale 23.50 1,280 30,082 186,433 Mar 12 04:05 PM Eckert Celia SVP, GENERAL COUNSEL Mar 11 '24 Sale 23.50 850 19,977 45,465 Mar 12 04:06 PM Kuch John J SR. VICE PRESIDENT & CFO Mar 11 '24 Sale 23.50 849 19,953 121,070 Mar 12 04:08 PM GUSTAFSON KURT A Director Mar 06 '24 Option Exercise 10.73 15,000 160,950 20,007 Mar 07 04:10 PM GUSTAFSON KURT A Director Mar 06 '24 Sale 23.18 14,000 324,453 6,007 Mar 07 04:10 PM Dahiyat Bassil I PRESIDENT & CEO Mar 05 '24 Sale 23.43 12,528 293,519 300,097 Mar 07 04:01 PM Desjarlais John R SR. VICE PRESIDENT & CSO Mar 05 '24 Sale 23.43 6,629 155,311 166,989 Mar 07 04:05 PM Kuch John J SR. VICE PRESIDENT & CFO Mar 05 '24 Sale 23.43 4,474 104,821 121,919 Mar 07 04:07 PM Eckert Celia SVP, GENERAL COUNSEL Mar 05 '24 Sale 23.43 3,892 91,186 33,226 Mar 07 04:03 PM Desjarlais John R SR. VICE PRESIDENT & CSO Feb 14 '24 Option Exercise 11.05 11,943 131,970 173,618 Feb 16 04:06 PM Desjarlais John R SR. VICE PRESIDENT & CSO Feb 13 '24 Option Exercise 11.05 68,057 752,030 215,783 Feb 14 02:23 PM GORMAN KEVIN CHARLES Director Feb 13 '24 Buy 19.12 53 1,013 5,060 Feb 15 04:02 PM Desjarlais John R SR. VICE PRESIDENT & CSO Feb 13 '24 Sale 19.38 54,108 1,048,743 161,675 Feb 14 02:23 PM Dahiyat Bassil I PRESIDENT & CEO Dec 29 '23 Option Exercise 11.05 65,001 718,261 357,929 Dec 29 04:24 PM Dahiyat Bassil I PRESIDENT & CEO Dec 29 '23 Sale 20.93 45,000 941,670 312,929 Dec 29 04:24 PM Dahiyat Bassil I PRESIDENT & CEO Jun 21 '23 Option Exercise 4.25 76,012 323,051 325,713 Jun 22 08:33 AM Dahiyat Bassil I PRESIDENT & CEO Jun 21 '23 Sale 26.19 33,497 877,286 292,216 Jun 22 08:33 AM
Index -
P/E -
EPS (ttm) -0.32
Insider Own 29.22%
Shs Outstand 21.02M
Perf Week 7.02%
Market Cap 38.59M
Forward P/E -
EPS next Y -
Insider Trans 0.63%
Shs Float 14.92M
Perf Month 3.39%
Income -6.73M
PEG -
EPS next Q -
Inst Own 24.68%
Short Float 0.22%
Perf Quarter 5.17%
Sales 18.36M
P/S 2.10
EPS this Y -
Inst Trans -1.20%
Short Ratio 0.62
Perf Half Y 74.29%
Book/sh 1.59
P/B 1.15
EPS next Y -
ROA -14.24%
Short Interest 0.03M
Perf Year 10.24%
Cash/sh 1.35
P/C 1.35
EPS next 5Y -
ROE -18.64%
52W Range 1.05 - 2.18
Perf YTD 10.24%
Dividend Est. -
P/FCF 42.88
EPS past 5Y -
ROI -18.08%
52W High -15.94%
Beta 0.79
Dividend TTM -
Quick Ratio 4.70
Sales past 5Y 5.26%
Gross Margin 91.19%
52W Low 74.29%
ATR (14) 0.14
Dividend Ex-Date Jul 25, 2014
Current Ratio 4.70
EPS Y/Y TTM -231.78%
Oper. Margin -32.95%
RSI (14) 50.90
Volatility 11.07% 6.29%
Employees 73
Debt/Eq 0.13
Sales Y/Y TTM 17.53%
Profit Margin -36.64%
Recom 1.00
Target Price 3.00
Option/Short Yes / Yes
LT Debt/Eq 0.11
EPS Q/Q 37.53%
Payout -
Rel Volume 2.13
Prev Close 2.07
Sales Surprise -
EPS Surprise -
Sales Q/Q 2.69%
Earnings May 02 AMC
Avg Volume 53.99K
Price 1.83
SMA20 2.48%
SMA50 0.95%
SMA200 13.43%
Trades
Volume 115,024
Change -11.59%
Date
Action
Analyst
Rating Change
Price Target Change
May-09-08 Downgrade
Merriman Curhan Ford
Buy → Neutral
May-01-07 Initiated
Merriman Curhan Ford
Buy
Mar-23-07 Initiated
MDB Capital Group
Buy
$7.50
May-02-24 09:54PM
04:17PM
(Associated Press Finance)
04:06PM
Apr-18-24 04:05PM
Mar-13-24 09:32AM
09:09AM
Loading…
09:09AM
Mar-12-24 04:24PM
(Associated Press Finance)
04:02PM
Feb-22-24 04:05PM
Jan-23-24 09:00AM
Jan-03-24 07:15AM
Dec-19-23 03:16PM
Nov-15-23 09:05AM
Nov-02-23 11:34AM
Nov-01-23 07:14PM
04:09PM
Loading…
04:09PM
(Associated Press Finance)
04:00PM
Oct-25-23 09:05AM
Oct-18-23 09:00AM
Oct-17-23 09:21AM
Oct-11-23 09:15AM
Sep-28-23 09:00AM
Sep-07-23 09:00AM
Aug-03-23 08:02AM
Aug-02-23 08:11AM
(Thomson Reuters StreetEvents) -5.17%
Aug-01-23 04:29PM
(Associated Press Finance)
04:05PM
Jul-27-23 09:00AM
Jul-18-23 09:05AM
Jul-12-23 08:11AM
08:00AM
Loading…
Jun-20-23 08:00AM
Jun-15-23 07:15AM
Jun-07-23 11:09AM
May-30-23 09:20AM
May-16-23 09:00AM
May-15-23 09:53AM
May-10-23 09:05AM
May-05-23 12:49PM
May-02-23 04:11PM
04:01PM
Apr-25-23 02:36PM
Apr-20-23 09:05AM
Mar-28-23 09:05AM
Mar-16-23 09:00AM
Mar-14-23 09:45AM
Mar-13-23 01:58AM
Mar-09-23 04:01PM
Mar-02-23 09:00AM
Feb-28-23 09:00AM
Feb-15-23 08:49AM
Jan-12-23 09:00AM
Dec-15-22 09:43AM
Dec-08-22 09:23AM
Nov-12-22 07:20AM
Nov-08-22 05:44AM
Oct-27-22 04:01PM
Oct-24-22 09:00AM
Oct-17-22 09:00AM
Oct-13-22 09:00AM
Oct-11-22 09:00AM
Oct-04-22 09:00AM
Sep-07-22 09:00AM
Aug-09-22 09:07AM
Aug-04-22 09:00AM
Aug-01-22 09:00AM
Jul-26-22 04:01PM
Jul-13-22 04:31PM
Jul-06-22 04:05PM
Jun-28-22 09:00AM
Jun-20-22 09:00AM
Jun-16-22 10:16AM
Jun-15-22 09:00AM
Jun-01-22 09:00AM
May-02-22 09:15AM
Apr-26-22 04:05PM
Apr-12-22 04:05PM
Mar-30-22 09:05AM
Mar-15-22 09:05AM
Mar-01-22 04:05PM
Feb-28-22 09:05AM
Feb-22-22 09:05AM
Feb-09-22 09:05AM
Feb-01-22 04:05PM
Jan-12-22 09:05AM
Dec-22-21 09:00AM
Dec-12-21 06:09AM
Dec-09-21 09:00AM
Nov-16-21 09:05AM
Oct-26-21 04:05PM
09:00AM
Oct-12-21 04:05PM
Oct-05-21 09:00AM
Sep-22-21 09:00AM
Sep-01-21 04:05PM
Aug-17-21 09:00AM
Aug-02-21 09:05AM
02:09AM
Jul-27-21 04:05PM
Jul-15-21 09:00AM
Jun-22-21 09:00AM
Aware, Inc. is a biometrics software and services company. The firm's products are used in government and commercial biometrics systems, which are capable of determining or verifying an individual's identity. It also provides interoperable, standards-compliant, field-proven biometric functionality, used to capture, verify, format, compress and decompress biometric images, as well as aggregate, analyze, process, and transport those images within biometric systems. The company was founded in 1986 and is headquartered in Burlington, MA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Eckel Robert A CEO & President Mar 15 '24 Buy 1.67 13,735 22,881 342,232 Mar 18 06:49 PM Traverse David K Principal Financial Officer Mar 14 '24 Buy 1.58 4,907 7,753 25,458 Mar 15 05:00 PM Johnstone Brent P Director Jan 02 '24 Option Exercise 0.00 20,907 0 180,476 Jan 03 05:45 PM Evee Gary Director Jan 02 '24 Option Exercise 0.00 14,620 0 50,557 Jan 03 05:44 PM Faubert Peter R. Director Jan 02 '24 Option Exercise 0.00 15,059 0 65,023 Jan 03 05:45 PM Connolly Brian D Director Jan 02 '24 Option Exercise 0.00 16,521 0 164,287 Jan 03 05:44 PM Eckel Robert A CEO & President Dec 14 '23 Buy 1.62 17,000 27,564 328,407 Dec 15 05:18 PM Eckel Robert A CEO & President Dec 13 '23 Buy 1.60 3,000 4,815 311,497 Dec 15 05:18 PM Eckel Robert A CEO & President Sep 19 '23 Option Exercise 0.00 20,000 0 303,497 Sep 20 04:27 PM Herman Craig A Chief Revenue Officer Aug 09 '23 Option Exercise 0.00 15,000 0 24,803 Aug 11 09:23 AM Connolly Brian D Director Jul 03 '23 Option Exercise 0.00 16,520 0 147,766 Jul 05 06:33 PM Johnstone Brent P Director Jul 03 '23 Option Exercise 0.00 20,906 0 159,569 Jul 05 06:35 PM Evee Gary Director Jul 03 '23 Option Exercise 0.00 14,620 0 35,937 Jul 05 06:34 PM Faubert Peter R. Director Jul 03 '23 Option Exercise 0.00 15,058 0 49,964 Jul 05 06:35 PM Eckel Robert A CEO & President May 26 '23 Buy 1.58 10,000 15,843 278,497 May 31 05:21 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite